NASDAQ:RPTX

Repare Therapeutics Competitors

$32.46
+1.68 (+5.46 %)
(As of 04/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$30.07
Now: $32.46
$32.88
50-Day Range
$25.89
MA: $29.80
$33.62
52-Week Range
$21.45
Now: $32.46
$46.44
Volume145,302 shs
Average Volume153,669 shs
Market Capitalization$1.20 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Repare Therapeutics (NASDAQ:RPTX) Vs. AVIR, BHVN, SAGE, HCM, EBS, and ARNA

Should you be buying RPTX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Repare Therapeutics, including Atea Pharmaceuticals (AVIR), Biohaven Pharmaceutical (BHVN), Sage Therapeutics (SAGE), Hutchison China MediTech (HCM), Emergent BioSolutions (EBS), and Arena Pharmaceuticals (ARNA).

Atea Pharmaceuticals (NASDAQ:AVIR) and Repare Therapeutics (NASDAQ:RPTX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

Profitability

This table compares Atea Pharmaceuticals and Repare Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Atea PharmaceuticalsN/AN/AN/A
Repare TherapeuticsN/AN/AN/A

Analyst Ratings

This is a breakdown of current recommendations and price targets for Atea Pharmaceuticals and Repare Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Atea Pharmaceuticals00403.00
Repare Therapeutics01513.00

Atea Pharmaceuticals currently has a consensus target price of $69.3333, suggesting a potential upside of 25.35%. Repare Therapeutics has a consensus target price of $39.40, suggesting a potential upside of 21.38%. Given Atea Pharmaceuticals' higher probable upside, analysts plainly believe Atea Pharmaceuticals is more favorable than Repare Therapeutics.

Insider and Institutional Ownership

64.8% of Repare Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Atea Pharmaceuticals and Repare Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atea PharmaceuticalsN/AN/AN/AN/AN/A
Repare TherapeuticsN/AN/AN/AN/AN/A

Summary

Repare Therapeutics beats Atea Pharmaceuticals on 3 of the 4 factors compared between the two stocks.

Biohaven Pharmaceutical (NYSE:BHVN) and Repare Therapeutics (NASDAQ:RPTX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

Profitability

This table compares Biohaven Pharmaceutical and Repare Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Biohaven PharmaceuticalN/A-1,091.41%-120.85%
Repare TherapeuticsN/AN/AN/A

Analyst Ratings

This is a breakdown of current recommendations and price targets for Biohaven Pharmaceutical and Repare Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biohaven Pharmaceutical021002.83
Repare Therapeutics01513.00

Biohaven Pharmaceutical currently has a consensus target price of $96.4545, suggesting a potential upside of 36.29%. Repare Therapeutics has a consensus target price of $39.40, suggesting a potential upside of 21.38%. Given Biohaven Pharmaceutical's higher probable upside, analysts plainly believe Biohaven Pharmaceutical is more favorable than Repare Therapeutics.

Insider and Institutional Ownership

99.4% of Biohaven Pharmaceutical shares are held by institutional investors. Comparatively, 64.8% of Repare Therapeutics shares are held by institutional investors. 19.1% of Biohaven Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Biohaven Pharmaceutical and Repare Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biohaven PharmaceuticalN/AN/A$-528,800,000.00($10.91)-6.49
Repare TherapeuticsN/AN/AN/AN/AN/A

Sage Therapeutics (NASDAQ:SAGE) and Repare Therapeutics (NASDAQ:RPTX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

Insider and Institutional Ownership

64.8% of Repare Therapeutics shares are held by institutional investors. 4.8% of Sage Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Sage Therapeutics and Repare Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sage Therapeutics-7,706.84%-63.81%-56.64%
Repare TherapeuticsN/AN/AN/A

Earnings and Valuation

This table compares Sage Therapeutics and Repare Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sage Therapeutics$6.87 million634.64$-680,240,000.00($13.38)-5.58
Repare TherapeuticsN/AN/AN/AN/AN/A

Repare Therapeutics has lower revenue, but higher earnings than Sage Therapeutics.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Sage Therapeutics and Repare Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sage Therapeutics08802.50
Repare Therapeutics01513.00

Sage Therapeutics currently has a consensus target price of $87.0625, suggesting a potential upside of 16.58%. Repare Therapeutics has a consensus target price of $39.40, suggesting a potential upside of 21.38%. Given Repare Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Repare Therapeutics is more favorable than Sage Therapeutics.

Summary

Repare Therapeutics beats Sage Therapeutics on 7 of the 10 factors compared between the two stocks.

Repare Therapeutics (NASDAQ:RPTX) and Hutchison China MediTech (NASDAQ:HCM) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Insider and Institutional Ownership

64.8% of Repare Therapeutics shares are owned by institutional investors. Comparatively, 33.5% of Hutchison China MediTech shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Repare Therapeutics and Hutchison China MediTech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Repare TherapeuticsN/AN/AN/A
Hutchison China MediTechN/AN/AN/A

Earnings & Valuation

This table compares Repare Therapeutics and Hutchison China MediTech's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Repare TherapeuticsN/AN/AN/AN/AN/A
Hutchison China MediTech$204.89 million20.81$-106,020,000.00($0.80)-36.63

Repare Therapeutics has higher earnings, but lower revenue than Hutchison China MediTech.

Analyst Recommendations

This is a summary of current ratings and target prices for Repare Therapeutics and Hutchison China MediTech, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Repare Therapeutics01513.00
Hutchison China MediTech00203.00

Repare Therapeutics presently has a consensus price target of $39.40, suggesting a potential upside of 21.38%. Hutchison China MediTech has a consensus price target of $40.00, suggesting a potential upside of 36.52%. Given Hutchison China MediTech's higher possible upside, analysts clearly believe Hutchison China MediTech is more favorable than Repare Therapeutics.

Summary

Repare Therapeutics beats Hutchison China MediTech on 3 of the 5 factors compared between the two stocks.

Repare Therapeutics (NASDAQ:RPTX) and Emergent BioSolutions (NYSE:EBS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Insider and Institutional Ownership

64.8% of Repare Therapeutics shares are owned by institutional investors. Comparatively, 80.2% of Emergent BioSolutions shares are owned by institutional investors. 14.1% of Emergent BioSolutions shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Repare Therapeutics and Emergent BioSolutions' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Repare TherapeuticsN/AN/AN/A
Emergent BioSolutions12.50%26.68%12.70%

Earnings & Valuation

This table compares Repare Therapeutics and Emergent BioSolutions' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Repare TherapeuticsN/AN/AN/AN/AN/A
Emergent BioSolutions$1.11 billion3.66$54.50 million$2.9126.07

Emergent BioSolutions has higher revenue and earnings than Repare Therapeutics.

Analyst Recommendations

This is a summary of current ratings and target prices for Repare Therapeutics and Emergent BioSolutions, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Repare Therapeutics01513.00
Emergent BioSolutions02502.71

Repare Therapeutics presently has a consensus price target of $39.40, suggesting a potential upside of 21.38%. Emergent BioSolutions has a consensus price target of $109.8333, suggesting a potential upside of 44.78%. Given Emergent BioSolutions' higher possible upside, analysts clearly believe Emergent BioSolutions is more favorable than Repare Therapeutics.

Summary

Emergent BioSolutions beats Repare Therapeutics on 7 of the 9 factors compared between the two stocks.

Repare Therapeutics (NASDAQ:RPTX) and Arena Pharmaceuticals (NASDAQ:ARNA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Insider and Institutional Ownership

64.8% of Repare Therapeutics shares are owned by institutional investors. Comparatively, 89.7% of Arena Pharmaceuticals shares are owned by institutional investors. 3.1% of Arena Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Repare Therapeutics and Arena Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Repare TherapeuticsN/AN/AN/A
Arena PharmaceuticalsN/A-33.17%-30.41%

Earnings & Valuation

This table compares Repare Therapeutics and Arena Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Repare TherapeuticsN/AN/AN/AN/AN/A
Arena Pharmaceuticals$806.43 million4.85$397.55 million$7.698.42

Arena Pharmaceuticals has higher revenue and earnings than Repare Therapeutics.

Analyst Recommendations

This is a summary of current ratings and target prices for Repare Therapeutics and Arena Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Repare Therapeutics01513.00
Arena Pharmaceuticals001503.00

Repare Therapeutics presently has a consensus price target of $39.40, suggesting a potential upside of 21.38%. Arena Pharmaceuticals has a consensus price target of $91.80, suggesting a potential upside of 41.75%. Given Arena Pharmaceuticals' higher possible upside, analysts clearly believe Arena Pharmaceuticals is more favorable than Repare Therapeutics.

Summary

Arena Pharmaceuticals beats Repare Therapeutics on 5 of the 8 factors compared between the two stocks.


Repare Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$55.31+2.2%$4.58 billionN/A0.00
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$70.77+1.9%$4.39 billionN/A-5.77Analyst Revision
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$74.68+2.6%$4.36 billion$6.87 million-7.22Analyst Report
Analyst Revision
News Coverage
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.30+0.2%$4.26 billion$204.89 million-36.63
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$75.86+2.0%$4.04 billion$1.11 billion24.39
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$64.76+2.4%$3.91 billion$806.43 million-9.17Unusual Options Activity
LEGN
Legend Biotech
1.2$27.81+2.3%$3.67 billion$64.39 million0.00
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$74.94+5.4%$3.67 billionN/A-21.35News Coverage
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$52.24+1.0%$3.64 billion$117.91 million-10.60
I-Mab logo
IMAB
I-Mab
1.4$47.86+7.9%$3.44 billion$4.31 million-1.66
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.68+0.3%$3.41 billion$114.62 million-7.53Analyst Revision
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$41.59+0.1%$3.34 billionN/A-5.61
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$47.13+1.0%$3.31 billion$306.98 million-6.74
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$20.43+0.2%$3.27 billion$339.08 million-11.88
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$46.31+6.7%$3.23 billion$36.13 million-69.12Unusual Options Activity
News Coverage
Insmed logo
INSM
Insmed
1.2$30.82+2.9%$3.18 billion$136.47 million-11.85
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$85.87+3.0%$3.11 billion$26.52 million-7.57
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$112.62+3.8%$3.04 billionN/A-56.03
Alkermes logo
ALKS
Alkermes
1.4$18.78+1.3%$2.99 billion$1.17 billion-40.83Unusual Options Activity
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$67.95+0.4%$2.98 billion$421.03 million23.93Analyst Report
Analyst Revision
Arvinas logo
ARVN
Arvinas
1.5$60.45+5.0%$2.95 billion$42.98 million-23.61
Organogenesis logo
ORGO
Organogenesis
1.0$22.98+0.6%$2.94 billion$260.98 million-383.00Gap Down
MorphoSys logo
MOR
MorphoSys
0.3$22.17+0.9%$2.92 billion$80.43 million105.58
Viela Bio logo
VIE
Viela Bio
0.8$53.01+0.0%$2.91 billion$50 million-7.55
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.59+0.3%$2.78 billion$644.77 million-10.36
OPKO Health logo
OPK
OPKO Health
1.9$4.06+3.0%$2.72 billion$901.90 million-22.55
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.43+1.1%$2.63 billion$306.49 million25.20
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.71+0.1%$2.57 billion$60,000.00-9.85News Coverage
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$44.05+0.5%$2.54 billion$25 million-8.81
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$40.97+3.8%$2.53 billionN/A-22.51
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$39.97+2.0%$2.48 billion$2.11 million-8.65
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.29+1.1%$2.46 billion$182.24 million-8.08
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$144.90+5.9%$2.41 billion$120.28 million-146.36
Cryoport logo
CYRX
Cryoport
1.9$51.64+1.3%$2.36 billion$33.94 million-89.03Insider Selling
ALX Oncology logo
ALXO
ALX Oncology
1.9$57.95+10.0%$2.33 billionN/A0.00
Amarin logo
AMRN
Amarin
1.6$5.84+1.5%$2.30 billion$429.76 million-116.78
Xencor logo
XNCR
Xencor
1.2$39.59+2.2%$2.29 billion$156.70 million-28.28News Coverage
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$44.30+1.2%$2.21 billion$963.01 million13.76News Coverage
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$30.49+2.7%$2.16 billion$15 million-15.96
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$26.18+0.3%$2.00 billion$23.90 million-16.26Analyst Revision
News Coverage
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$27.91+0.8%$1.99 billion$410,000.00-6.07
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$51.89+2.1%$1.94 billionN/A-19.29
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$62.10+10.3%$1.91 billionN/A-26.43Gap Down
Kura Oncology logo
KURA
Kura Oncology
1.6$28.62+0.2%$1.89 billionN/A-17.56
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$24.53+3.7%$1.88 billion$103.54 million-18.44
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$117.02+0.0%$1.88 billionN/A-10.57
MORF
Morphic
1.1$57.73+2.8%$1.87 billion$16.98 million-37.01Insider Selling
News Coverage
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.16+2.1%$1.85 billion$34.51 million-17.23
FibroGen logo
FGEN
FibroGen
1.8$19.89+6.6%$1.82 billion$256.58 million-7.62High Trading Volume
Analyst Revision
MacroGenics logo
MGNX
MacroGenics
1.4$30.07+3.6%$1.80 billion$64.19 million-9.61
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.